Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Che-Kai Tsao

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Clinical Medicine Insights. Oncology|June 23, 2011
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancerChe-Kai Tsao, Sonia Seng, William K Oh, et al.
Targeted Oncology|December 3, 2025
Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysisSusu Zhou, Devashish Desai, Noriko Kishi, et al.
Current Opinion in Urology|April 5, 2012
Overcoming castration resistance in prostate cancerChe-Kai Tsao, Alexander C Small, Matthew D Galsky, et al.
CA: a Cancer Journal for Clinicians|April 27, 2012
Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successesMatthew D Galsky, Alexander C Small, Che-kai Tsao, et al.
Expert Review of Anticancer Therapy|December 21, 2012
Emerging personalized approaches for the management of advanced urothelial carcinomaChe-Kai Tsao, Benjamin A Gartrell, William K Oh, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 16, 2013
Metabolic and toxicological considerations of newly approved prostate cancer drugsChe-Kai Tsao, Bobby Liaw, Tiffany Yee, et al.
Cancers|November 13, 2025
Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment OutcomesJing Huang, Ademola Ojo, Serena Tsao, et al.
Clinical Genitourinary Cancer|April 7, 2024
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled TrialsSusu Zhou, Parissa Alerasool, Noriko Kishi, et al.
Current Treatment Options in Oncology|September 16, 2017
Management of Atypical Renal Cell CarcinomasBobby C Liaw, Reza Mehrazin, Charles Baker, et al.
BJU International|September 19, 2012
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)Che-Kai Tsao, Matthew D Galsky, Alexander C Small, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Clinical Medicine Insights. Oncology|June 23, 2011
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancerChe-Kai Tsao, Sonia Seng, William K Oh, et al.
Targeted Oncology|December 3, 2025
Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysisSusu Zhou, Devashish Desai, Noriko Kishi, et al.
Current Opinion in Urology|April 5, 2012
Overcoming castration resistance in prostate cancerChe-Kai Tsao, Alexander C Small, Matthew D Galsky, et al.
CA: a Cancer Journal for Clinicians|April 27, 2012
Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successesMatthew D Galsky, Alexander C Small, Che-kai Tsao, et al.
Expert Review of Anticancer Therapy|December 21, 2012
Emerging personalized approaches for the management of advanced urothelial carcinomaChe-Kai Tsao, Benjamin A Gartrell, William K Oh, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 16, 2013
Metabolic and toxicological considerations of newly approved prostate cancer drugsChe-Kai Tsao, Bobby Liaw, Tiffany Yee, et al.
Cancers|November 13, 2025
Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment OutcomesJing Huang, Ademola Ojo, Serena Tsao, et al.
Clinical Genitourinary Cancer|April 7, 2024
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled TrialsSusu Zhou, Parissa Alerasool, Noriko Kishi, et al.
Current Treatment Options in Oncology|September 16, 2017
Management of Atypical Renal Cell CarcinomasBobby C Liaw, Reza Mehrazin, Charles Baker, et al.
BJU International|September 19, 2012
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)Che-Kai Tsao, Matthew D Galsky, Alexander C Small, et al.
Pageof 8